Scailyte raises €3.3M Pre-Series A round
9 June 2020· Basel, Switzerland· health, precision_medicine, ai, biotech, pure_software, b2b
to further advance its biomarker discovery platform, further build upon Scailyte's biomarker and IVD pipeline, and drive the development of the first clinical applications using single-cell biomarkers
Investors
LeadSwisscom Ventures
Also participating
existing shareholdersHEMEX4FO Venturesprivate investor
About Scailyte
Stage
Series A
Headquarters
Basel, Switzerland
Founded
2017
Team Size
21–50
Sectors
healthprecision_medicineaibiotechpure_softwareb2b